27 Sep 2023

ObsEva Files half Year 2023 Financial Statements

13 Jul 2023

ObsEva Recovers Full Worldwide Rights on Nolasiban

30 Jun 2023

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

08 Jun 2023

Annual General Meeting 2023

02 May 2023

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

28 Apr 2023

ObsEva Annual Report 2022

20 Apr 2023

ObsEva Announces Change of Central Securities Depositary

20 Apr 2023

ObsEva Announces Change of Central Securities Depositary

31 Mar 2023

ObsEva Files Year End 2022 Financial Statements

15 Mar 2023

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

15 Mar 2023

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

13 Mar 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

13 Mar 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

24 Feb 2023

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

24 Feb 2023

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland